Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Chevron Corp (CVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Chevron Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $227.23 (market cap $29.97B), while Chevron Corp trades at $197.79 (market cap $385.65B). The key difference: Chevron Corp is far larger — about 12.9× Alnylam Pharmaceuticals, Inc.'s market cap, and Chevron Corp pays a 3.62% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | CVX | |
|---|---|---|
Market Cap | $29.97B | $385.65B |
Sector | Health | Energy |
52-Week High | $491.22 | $211.14 |
52-Week Low | $205.48 | $146.72 |
Enterprise Value | $27.93B | $414.20B |
Volume | — | 9,807,834 |
Dividend Yield | — | 3.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
CVX trades at $196.66, up 0.9% today, with a bullish technical signal supported by moving averages. The stock has beaten EPS estimates in recent quarters, though revenue and net income have declined from 2022 peaks. Analyst consensus is strongly bullish with a $214.25 price target, and the company maintains solid profitability with a 9.87% net margin and 12.25% ROE. Recent news highlights Chevron's $13.8 billion investment in Argentina's Vaca Muerta shale and geopolitical factors affecting oil prices.
Outlook remains positive driven by high oil prices and strategic investments, but risks include volatile energy markets and execution of large capital projects. The stock offers value with a P/E of 18.93 and consistent dividends, though investors face headwinds from declining profit margins and geopolitical tensions impacting global supply chains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →
